Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZIOverviewHYMPAVZI in ActionEfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& AdminDosingPen OverviewInjection OverviewPatient StoriesPatient
StoriesMeet a Real PatientIdentifying Potential PatientsResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Mean ABR for all measured bleed categories1Mean ABR for all measured bleed categories1

BASIS Secondary Endpoints

OLE Secondary Endpoints

HYMPAVZI demonstrated superiority over on-demand factor-based treatment across secondary bleeding endpoints after 12 months (all, p<0.0001)1

ABR of bleed categories vs on-demand factor-based treatment*

 Total bleeds (95% CI: on-demand 42.09, 59.32; HYMPAVZI 5.10, 10.75), joint bleeds (95% CI: on-demand 27.84, 42.79; HYMPAVZI 1.82, 4.46), spontaneous bleeds (95% CI: on-demand 25.79, 41.28; HYMPAVZI 1.62, 3.72), target joint bleeds (95% CI: on-demand 18.27, 32.53; HYMPAVZI 1.07, 3.18).HYMPAVZI demonstrated non-inferiority to routine factor-based prophylaxis treatment across secondary bleeding endpoints after 12 months1

ABR of bleed categories vs routine factor-based prophylaxis treatment*

 Total bleeds (95% CI: factor 6.02, 11.77; HYMPAVZI 4.14, 7.82), joint bleeds (95% CI: factor 3.36, 8.02; HYMPAVZI 2.59, 5.67), spontaneous bleeds (95% CI: factor 3.57, 8.22; HYMPAVZI 2.25, 5.31), target joint bleeds (95% CI: factor 1.60, 5.15; HYMPAVZI 1.26, 3.76).*After 12 months of active treatment with the once-weekly 150 mg SC dose of HYMPAVZI.1Meet Peter, a real HYMPAVZI patient

Hear Peter's experience using once-weekly HYMPAVZI1

 See Peter's story Loading See Peter's story LoadingABR=annualized bleed rate; CI=confidence interval; OLE=open-label extension; SC=subcutaneous.Reference:1. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2025. 
OLE Study limitations1,2

The OLE Study is an ongoing observational study in which no formal hypothesis testing was conducted.​ Not all patients in the BASIS Study rolled over into the OLE Study​

  • Enrollment in OLE studies may favorably select patients who are responsive to treatment
  • Results should be interpreted with caution as they may represent chance findings
Mean ABR among patients on prior on-demand treatment who continued HYMPAVZI in the OLE Study for up to an additional 16 months1* Total bleeds (95% CI: 3.25, 8.00), joint bleeds (95% CI: 1.07, 3.26), spontaneous bleeds (95% CI: 1.22, 5.29), target joint bleeds (95% CI: 0.51, 1.58).Mean ABR across bleed categories among patients on prior routine prophylaxis treatment who continued HYMPAVZI in the OLE Study for up to an additional 16 months1* Total bleeds (95% CI: 1.70, 4.38), joint bleeds (95% CI: 1.14, 3.08), spontaneous bleeds (95% CI: 0.96, 2.73), target joint bleeds (95% CI: 0.36, 2.27).BASIS Study results are based on the 150 mg SC QW dose of HYMPAVZI after 12 months of active treatment, and OLE Study results include both 150 mg and 300 mg SC QW doses of HYMPAVZI.1,2Up to an additional 16 months of treatment with HYMPAVZI after completing the 12-month ATP (mean follow-up 7 months). All patients who completed the Phase 3 BASIS Study and enrolled into the OLE Study on or before March 10, 2023, are included in this dataset.1p values for the null hypothesis say that the ratio=1/2 for all bleed-related parameters.2Meet Peter, a real HYMPAVZI patient

Hear Peter's experience using once-weekly HYMPAVZI2

 See Peter's story Loading See Peter's story LoadingABR=annualized bleed rate; CI=confidence interval; OLE=open-label extension; QW=once weekly; SC=subcutaneous.References:1. Data on file. Pfizer Inc.; 2025. 2. HYMPAVZI. Prescribing Information. Pfizer Inc.; 2025.
Efficacy HYMPAVZI safety profile

Safety of HYMPAVZI was evaluated in the Phase 3 BASIS Study1

 See safety data Loading

HYMPAVZI is a registered trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-HYM-USA-0601
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationVenous thrombotic events were reported in clinical studies with HYMPAVZI. Patients with independent risk factors for thromboembolic events may be at increased risk of thromboembolic events with use of HYMPAVZI. Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. A serious adverse reaction of venous thrombosis occurred in 0.9% of patients (1/116) in the open-label extension study. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).IndicationsHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.